Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 53

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 53
---
 decided to recall the affected batch from the       
 market as a measure to help eliminate the counterfeit product, in addition       
 to launching an information campaign. Both actions were carried out in           
 collaboration with the competent authorities to protect patient safety.          
 Counterfeit drug prevention                                                      
 system                                                                           
 The counterfeiting of medicines and advanced diagnostic systems poses            
 a global risk to patient safety and public health. Plasma-derived medicines      
 are typically prescription-only drugs and are primarily administered in          
 hospital settings.                                                               
 Grifols collaborates with regulatory authorities to investigate and analyze      
 suspected cases of counterfeit products. The company has implemented             
 an Anti-Counterfeiting Policy to help prevent, detect and report counterfeit     
 products. Under this policy, any suspected or confirmed cases of                 
 counterfeit medicines must be promptly reported to the relevant regulatory       
 authorities in compliance with applicable regulations.                           
 Committed to supporting regulatory authorities in preventing                     
 counterfeiting, Grifols uses track-and-trace technology to comply with           
 product serialization and aggregation requirements in certain countries          
 and regions. Beyond these obligatory measures, Grifols implements                
 additional anti-counterfeiting safeguards, including assigning unique            
 codes to vials before marketing any plasma-derived product and adding            
 holographic seals to packaging to ensure its integrity and authenticity.         
 Grifols undergoes regular internal audits and external inspections to verify     
 compliance with applicable regulations and conducts due diligence with           
 customers and distributors to confirm they hold the necessary licenses to        
 distribute its products.                                                         
 Furthermore, Grifols outlines detailed measures for addressing suspected         
 counterfeiting in its contracts and quality agreements with third parties,       
 where applicable. Since 2021, Grifols has not been aware of any incidents        
 leading to raids, seizures, arrests or the filing of criminal charges related to 
 counterfeit products.                                                            |

| 2024 Non-Financial Information Statement and Sustainability reporting 155     
 General Environment Social Governance Annexes                                 
 Patients and healthcare professionals                                         
 Building trust-based relationships through                                    
 transparency                                                                  
 By integrating the knowledge, experience and perspectives of patients,        
 patient organizations, healthcare professionals and healthcare                
 organizations, Grifols is able to develop increasingly innovative and         
 personalized treatments, diagnostics, technologies, services and solutions.   
 Patient relations through                                                     
 patient organizations                                                         
 Patient associations and organizations play a vital role in global healthcare 
 systems. They contribute to patient education, advocate for patient rights    
 and support clinical research. At Grifols, these organizations increasingly   
 influence decision-making. Actions and initiatives involving these groups     
 are coordinated and managed by the